The company’s lead drug candidate is composed of 30 sufentanil tablets delivered sublingually using a disposable, pre-filled single-dose applicator. Dsuvia is investigational and not approved in any country.
The 4 late-phase studies enrolled 480 patients total. In 2 randomized studies, enrolled patients underwent bunionectomy and abdominal surgeries and were treated for post-operative pain. The other 2 trials evaluated Dsuvia in the emergency department and in older, post-operative patients.